These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 30007530)
1. Factors associated with how often community pharmacists offer and dispense naloxone. Carpenter DM; Dhamanaskar AK; Gallegos KL; Shepherd G; Mosley SL; Roberts CA Res Social Adm Pharm; 2019 Dec; 15(12):1415-1418. PubMed ID: 30007530 [TBL] [Abstract][Full Text] [Related]
2. Assessing pharmacists' readiness to dispense naloxone and counsel on responding to opioid overdoses. Melaragni F; Levy C; Pedrazzi J; Andersen M J Am Pharm Assoc (2003); 2019; 59(4):550-554.e2. PubMed ID: 31109812 [TBL] [Abstract][Full Text] [Related]
3. Pharmacists' readiness to provide naloxone in community pharmacies in West Virginia. Thornton JD; Lyvers E; Scott VGG; Dwibedi N J Am Pharm Assoc (2003); 2017; 57(2S):S12-S18.e4. PubMed ID: 28163027 [TBL] [Abstract][Full Text] [Related]
4. Attitudes and availability: A comparison of naloxone dispensing across chain and independent pharmacies in rural and urban areas in Alabama. Sisson ML; McMahan KB; Chichester KR; Galbraith JW; Cropsey KL Int J Drug Policy; 2019 Dec; 74():229-235. PubMed ID: 31698165 [TBL] [Abstract][Full Text] [Related]
5. Identifying barriers to dispensing naloxone: A survey of community pharmacists in North Carolina. Rudolph SE; Branham AR; Rhodes LA; Hayes HH; Moose JS; Marciniak MW J Am Pharm Assoc (2003); 2018; 58(4S):S55-S58.e3. PubMed ID: 30006187 [TBL] [Abstract][Full Text] [Related]
6. North Carolina community pharmacists' buprenorphine dispensing practices and attitudes. Carpenter D; Lambert KV; Harless JC; Wilson CG; Davis SA; Zule WA; Ostrach B J Am Pharm Assoc (2003); 2022; 62(5):1606-1614. PubMed ID: 35643625 [TBL] [Abstract][Full Text] [Related]
7. Pharmacists and Naloxone: Barriers to Dispensing and Effectiveness of an Educational Outreach Program. Hanson KA; Smart MH; Mandava MR; Carkovic E; Aslamy M; Lee TA; Pickard AS J Am Pharm Assoc (2003); 2023; 63(2):608-613.e3. PubMed ID: 36631342 [TBL] [Abstract][Full Text] [Related]
8. Pharmacists' naloxone services beyond community pharmacy settings: A systematic review. Rawal S; Osae SP; Cobran EK; Albert A; Young HN Res Social Adm Pharm; 2023 Feb; 19(2):243-265. PubMed ID: 36156267 [TBL] [Abstract][Full Text] [Related]
9. Perpetuating stigma or reducing risk? Perspectives from naloxone consumers and pharmacists on pharmacy-based naloxone in 2 states. Green TC; Case P; Fiske H; Baird J; Cabral S; Burstein D; Schwartz V; Potter N; Walley AY; Bratberg J J Am Pharm Assoc (2003); 2017; 57(2S):S19-S27.e4. PubMed ID: 28214219 [TBL] [Abstract][Full Text] [Related]
10. CONSIDER New Mexico: Effects of naloxone training among pharmacists and pharmacy technicians. Cruz TH; Bachyrycz A; Rodriguez DE; Ma X; Roberts MH; Chambers S; Rafi J; Sanchez A; Bakhireva L J Am Pharm Assoc (2003); 2022; 62(3):757-765. PubMed ID: 35016857 [TBL] [Abstract][Full Text] [Related]
11. Impact of a Multicomponent Educational Intervention on Community Pharmacy-Based Naloxone Services Implementation: A Pragmatic Randomized Controlled Trial. Hohmann LA; Fox BI; Garza KB; Wang CH; Correia C; Curran GM; Westrick SC Ann Pharmacother; 2023 Jun; 57(6):677-695. PubMed ID: 36047381 [TBL] [Abstract][Full Text] [Related]
12. Implementation of a naloxone dispensing program in a grocery store-based community pharmacy. Wilkerson DM; Groves BK; Mehta BH Am J Health Syst Pharm; 2020 Mar; 77(7):511-514. PubMed ID: 32086505 [No Abstract] [Full Text] [Related]
13. A standardized team-based approach for identifying naloxone-eligible patients in a grocery store pharmacy. Sexton SM; Armstrong A; Gatton O; Rhodes LA; Marciniak MW J Am Pharm Assoc (2003); 2019; 59(4S):S95-S100. PubMed ID: 31231001 [TBL] [Abstract][Full Text] [Related]
14. Impact of student pharmacist-led naloxone academic detailing at community pharmacies in Texas. Evoy KE; Groff L; Hill LG; Godinez W; Gandhi R; Reveles KR J Am Pharm Assoc (2003); 2020; 60(1):81-86. PubMed ID: 31669417 [TBL] [Abstract][Full Text] [Related]
15. Barriers and facilitators to dispensing of intranasal naloxone by pharmacists. Bakhireva LN; Bautista A; Cano S; Shrestha S; Bachyrycz AM; Cruz TH Subst Abus; 2018; 39(3):331-341. PubMed ID: 29043922 [TBL] [Abstract][Full Text] [Related]
16. Self-reported clinical pharmacy service provision in Austria: an analysis of both the community and hospital pharmacy sector-a national study. Deibl S; Mueller D; Kirchdorfer K; Stemer G; Hoppel M; Weidmann AE Int J Clin Pharm; 2020 Aug; 42(4):1050-1060. PubMed ID: 32494989 [TBL] [Abstract][Full Text] [Related]
17. Addressing the opioid epidemic through community pharmacy engagement: Study protocol for a randomized controlled trial. Gamble A; Mashburn T; Kennelty KA; Look KA; Westrick SC; Evon DM; Tudor G; Carpenter DM Contemp Clin Trials; 2022 Oct; 121():106920. PubMed ID: 36096283 [TBL] [Abstract][Full Text] [Related]
18. Perceived barriers to provision of medication therapy management services (MTMS) and the likelihood of a pharmacist to work in a pharmacy that provides MTMS. Blake KB; Madhavan SS Ann Pharmacother; 2010 Mar; 44(3):424-31. PubMed ID: 20179254 [TBL] [Abstract][Full Text] [Related]
19. What is known about community pharmacy supply of naloxone? A scoping review. Nielsen S; Van Hout MC Int J Drug Policy; 2016 Jun; 32():24-33. PubMed ID: 26949189 [TBL] [Abstract][Full Text] [Related]
20. Pharmacists' naloxone offering and dispensing practices. Thakur T; Kile M; Chewning B J Opioid Manag; 2022; 18(2):133-141. PubMed ID: 35476882 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]